Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 28;59(3):39-44.
doi: 10.47895/amp.vi0.9439. eCollection 2025.

Clinical, Biochemical, and Radiologic Profiles of Filipino Patients with 6-Pyruvoyl-Tetrahydrobiopterin Synthase (6-PTPS) Deficiency and their Neurodevelopmental Outcomes

Leniza G de Castro-Hamoy  1   2   3 , Ma Anna Lourdes A Moral  1 , Loudella V Calotes-Castillo  1 , Mary Ann R Abacan  1   2 , Cynthia P Cordero  4 , Maria Lourdes C Pagaspas  1   5 , Ebner Bon G Maceda  1   2 , Sylvia C Estrada  1   2 , Mary Anne D Chiong  1   6
Affiliations

Clinical, Biochemical, and Radiologic Profiles of Filipino Patients with 6-Pyruvoyl-Tetrahydrobiopterin Synthase (6-PTPS) Deficiency and their Neurodevelopmental Outcomes

Leniza G de Castro-Hamoy et al. Acta Med Philipp. .

Abstract

Background: Six-pyruvoyl-tetrahydrobiopterin synthase (6-PTPS) deficiency is an inherited metabolic disorder which results in tetrahydrobiopterin (BH4) deficiency causing hyperphenylalaninemia.

Objective: This study aimed to describe the clinical, biochemical, and radiologic profiles, and neurologic and developmental outcomes of patients diagnosed with 6-pyruvoyl tetrahydrobiopterin (PTPS) deficiency through newborn screening and confirmed by BH4 loading test, pterin analysis, and gene sequencing who were following-up with the metabolic team.

Methods: The research was a single-center descriptive case series study design that was done at the Philippine General Hospital, a tertiary government hospital. The clinical, biochemical, radiologic profiles and neurodevelopmental evaluation of each patient were described.

Results: Nine patients from 1 year 2 months to 14 years 5 months of age were enrolled in the study. Clinical manifestations before treatment were hypotonia, poor suck, and seizure. The most common clinical manifestation even after treatment initiation was seizure. The mean phenylalanine level on newborn screening was 990.68 umol/L, but after treatment was started, mean levels ranged from 75.69 to 385.09 umol/L. Two of the patients had focal atrophy of the posterior lobe on brain imaging. Pathogenic variants on molecular analysis were all missense, with two predominant variants, c.155A>G and c.58T>C. Eight of the nine patients had varying degrees of developmental delay or intellectual disability, while the remaining patient had signs of a learning disorder.

Conclusion: Newborn screening has played a crucial role in the early identification and management of patients with hyperphenylalaninemia due to 6-PTPS deficiency. Confirmation of diagnosis through determination of DHPR activity, urine pterins and/or molecular analysis is necessary for appropriate management. However, despite early initiation of treatment, neurodevelopmental findings of patients with 6-PTPS deficiency were still unsatisfactory.

Keywords: 6-PTPS deficiency; hyperphenylalaninemia; tetrahydrobiopterin.

PubMed Disclaimer

Conflict of interest statement

All authors declared no conflicts of interest.

Figures

Figure 1
Figure 1
The biochemical pathway of tetrahydrobiopterin metabolism (BH4). GTPCH – GTP cyclohydrolase I, PTPS – 6-pyruvoyl tetrahydropterin synthase, SR – sepiapterin reductase, DHPR – dihydropteridine reductase, PCD – pterin-4a-carbinolamine dehydratase
See this image and copyright information in PMC

References

    1. Almannai M, Felemban R, Saleh MA, Faqeih EA, Alasmari A, AlHashem A, et al. . 6-pyruvoyltetrahydropterin synthase deficiency: review and report of 28 Arab subjects. Pediatr Neurol. 2019. Jul;96: 40-7. doi: 10.1016/j.pediatrneurol.2019.02.008. PMID: 30926181. - DOI - PubMed
    1. Demos MK, Waters PJ, Vallance HD, Lillquist Y, Makhseed N, Hyland K, et al. . 6-pyruvoyl-tetrahydropterin synthase deficiency with mild hyperphenylalaninemia. Ann Neurol. 2005. Jul;58(1):164-7. doi: 10.1002/ana.20532. PMID: 15984017. - DOI - PubMed
    1. Blau N, Thony B, Cotton RGH, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. pp. 1725-1776.
    1. Hui J, Chong SC, Law LK, Lee LK, Chang S, Yau P, et al. . One too many: intellectual disability secondary to undiagnosed phenylketonuria. Hong Kong Med J. 2016. Oct;22(5):506-8. doi: 10.12809/hkmj144500. PMID: 27738300. - DOI - PubMed
    1. Opladen T, López-Laso E, Cortès-Saladelafont E, Pearson TS, Sivri HS, Yildiz Y, et al. . Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis. 2020. May 26;15(1):126. doi: 10.1186/s13023-020-01379-8. PMID: 32456656; PMCID: . Erratum in: Orphanet J Rare Dis. 2020 Aug 5;15(1):202. doi: 10.1186/s13023-020-01464-y. PMID: 32758270. - DOI - PMC - PubMed

LinkOut - more resources